Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesFiltered
Popular posts, ranked by community votes and recency.#SymptomMgmtAI researchClear filters
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Longitudinal Gut Microbiome Study in Relapsing-Remitting MS Patients

In a study of 29 treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS), gut microbiota composition and diversity remained stable over one year. While there was a trend indicating that worsening disability (measured by EDSS) correlated with increased microbiome instability, this did not reach statistical significance. Additionally, GFAP levels increased significantly, while NfL levels decreased and S100B levels remained unchanged.

What this does not proveThe study's exploratory analyses noted that significant associations found did not hold after adjustments for multiple testing. Moreover, the small sample size necessitates larger longitudinal studies to better understand these relationships.
#GutHealth#Disability#Biomarkers#SymptomMgmtRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42795661AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

CAR-T Cell Therapy and Gut Microbiota Modulation in MS

Research suggests that CAR-T cells can effectively target and eliminate B cells in multiple sclerosis (MS). Additionally, the gut microbiota is found to play a significant role in immune system balance related to MS.

What this does not proveThe findings do not demonstrate clinical efficacy for CAR-T therapy in MS patients, nor do they clarify how gut microbiota modulation influences MS symptoms or progression.
#CARTCellTherapy#GutMicrobiota#SymptomMgmt#WellnessRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42793314AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Mast Cells in Neuroimmune Interactions: Mechanisms, Pathophysiological Roles, and Therapeutic Implications

A systematic review was conducted on the role of mast cells in neuroimmune interactions and their implications in multiple sclerosis (MS) among other disorders. It discussed various dysfunctions and therapeutic approaches targeting mast cells.

What this does not proveThe review does not provide clinical trial data or specific research outcomes related to MS, limiting its applicability in predicting treatment effects.
#MastCells#Neurodegeneration#Inflammation#SymptomMgmtRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42799832AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyCase reportPeer review unconfirmed

Human Case Report of Amyotrophic Lateral Sclerosis and Multiple Sclerosis

A case report diagnosed ALS in a patient who had lived with MS for decades. It emphasized the need for broader differential diagnosis when symptoms overlap, which could indicate another neurological condition.

What this does not proveThe limited number of documented cases significantly restricts generalizability.
#ALS#SymptomMgmtRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42789802AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Cannabidiol (CBD) and Its Neuroprotective Effects in Animal Models of Multiple Sclerosis and Other Neurodegenerative Diseases

CBD demonstrates anti-inflammatory, antioxidant, mitochondria-protective, and neuroprotective properties in preclinical models related to multiple sclerosis and other neurodegenerative diseases. Clinical evidence, however, primarily addresses symptoms like agitation and sleep disturbances without proving disease modification.

What this does not proveThe clinical evidence remains preliminary and does not show proven disease modification. Key barriers include inconsistent bioavailability and insufficient understanding of exposure-response relationships.
#CBD#Neuroprotection#SymptomMgmt#WellnessRelevant to Neurologist, Pharmacologist
View abstract on PubMedPMID 42790169AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer-reviewed

Mesenchymal Stem Cell Transplantation in Progressive Multiple Sclerosis: A Systematic Review

A systematic review assessed the efficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis. It was identified as a correction to previous findings, indicating an update rather than new data.

What this does not proveThe study does not present new data on the efficacy or safety of the treatment, only correcting earlier findings without additional evidence.
#StemCellTherapy#Wellness#SymptomMgmt#ImmunologyRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42798841AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyOtherPeer review unconfirmed

Work Stressors and Resources Impacting Employees with Multiple Sclerosis

A qualitative study explored how employees with multiple sclerosis perceive work-related stressors and resources. Key findings indicated that adverse working conditions led to reduced working hours and potential career changes. Reported stressors negatively affected symptoms like fatigue and cognitive disturbances, while resources helped enhance work capability and provide motivation.

What this does not proveThe study is qualitative and does not establish causal relationships or efficacy of interventions.
#WorkplaceWellness#SymptomMgmt#StressManagement#EmployeeSupportRelevant to Neurologist, Occupational Therapist
View abstract on PubMedPMID 42786464AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Eating-Related Tendencies in Adults with Multiple Sclerosis

A study with 382 adults with multiple sclerosis identified distinct eating-related profiles. These profiles were categorized into five classes: low difficulties, moderate mixed tendencies, two emotional eating/restraint profiles, and dysregulated overeating. Higher self-management scores were observed in restraint-related profiles.

What this does not proveThe study does not establish clinical classification or treatment recommendations, and it merely serves as a basis for future research.
#DietNutrition#SymptomMgmt#Wellness#SelfManagementRelevant to Neurologist, Dietitian
View abstract on PubMedPMID 42796967AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedObservationalPeer review unconfirmed

Survey on Internet Use for MS Information Among Participants

An online survey involving 152 MS participants highlighted that 99% used the Internet to seek MS-related information, with 84% searching for medicine specifics. MS specialists were the most trusted source, but 54.4% had concerns regarding the quality of online information.

What this does not proveFindings are exploratory and drawn from a specific charity's engaged members, lacking a calculable response rate. They require validation in broader, more representative samples.
#EBV#SymptomMgmt#Wellness#DietNutritionRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42793465AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedInterventionalPeer-reviewed

Effects of Mixed-Amphetamine Salts on Cognitive Function in MS Model

In a randomized, controlled study of 123 participants with MS over 12 weeks, no significant differences were found in cognitive function as measured by the Symbol Digit Modalities Test (SDMT) between those receiving mixed-amphetamine salts (MAS-XR) and a placebo (p = 0.545). There were significant differences in psychosocial measures for the 20 mg MAS-XR group compared to placebo (p = 0.041).

What this does not proveThe study did not show that MAS-XR is effective for cognitive impairment in MS, and the age mismatch between groups could impact the results.
#CognitiveImpairment#Fatigue#QualityOfLife#SymptomMgmtRelevant to Neurologist, Psychiatrist
View abstract on PubMedPMID 42800227AI summary of a published abstract. Not medical advice.